摘要
目的研究多西他赛联合mFOLFOX方案化疗治疗进展期胃癌的疗效及其毒副作用。方法31例患者应用该方案起止时间为2005年6月至2007年3月。化疗方案:多西他赛60mg/m2,d1,滴注;OXA130mg/m2,d2,滴注;5-Fu2.8g/m2,civ,46h;CF300mg,d2,5-Fu前2h滴注,每3周为1周期,至少应用2周期。观察应用该方案肿瘤缓解情况及化疗的毒副反应。结果CR3例(9.7%),PR12例(38.7%),SD8例(25.8%),PD8例(25.8%),有效率48.4%。主要不良反应为骨髓抑制、外周神经毒性、脱发。无治疗相关性死亡。结论多西他赛联合mFOLFOX方案治疗进展期胃癌近期疗效较好,药物毒副作用可耐受。
Objective To elavulate the efficacy and toxicity of the combination of docetaxel and mFOLFOX in the treatment of advanced gastric cancer. Methods From June 2005 to March 2007,31 pa- tients with advanced gastric cancer were treated with docetaxel and mFOLFOX chemotherapy. The chemotherapy regimen consisted of docetaxel 60 mg/m2 （ day 1 ）, oxaliplatin 130 mg/m2 （ day 2 ） plus fluorouracil 2. 8 g/m2 continuous iv 46 h （day2）, leucovorin 300 mg （day 2 ） before use of fluorouracil, 3 weeks constituted one cycle, every patient was treated with more than 2 cycles. The response of the tumor and chemotherapy toxicity were observed for each patient. Results The overall response rate was 48.4% （9. 7% CR, 38. 7% PR）, SD was 25.8% and PD was 25.8%. The most common toxic reactions were bone marrow suppression, peripheral neurotoxicity and alopecia,but there was no chemotherapy-related death. Conclusion The combination of docetaxel plus mFOLFOX is a very effective and well tolerated regimen in the treatment of advanced gastric cancer.
出处
《中国肿瘤临床与康复》
2009年第6期544-546,共3页
Chinese Journal of Clinical Oncology and Rehabilitation
